Eli Lilly LLY Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $65.18B+44.7% | $45.04B+32.0% | $34.12B+19.6% | $28.54B+0.8% | ||
| $11.05B+31.3% | $8.42B+18.9% | $7.08B+6.8% | $6.63B-9.3% | ||
| $54.13B+47.8% | $36.63B+35.4% | $27.04B+23.4% | $21.91B+4.3% | ||
| 83%+1.7pp | 81.3%+2.1pp | 79.2%+2.5pp | 76.8%+2.6pp | ||
| $13.34B+21.3% | $10.99B+18.0% | $9.31B+29.5% | $7.19B+3.8% | ||
| $11.09B+29.1% | $8.59B+16.1% | $7.4B+15.0% | $6.44B+0.1% | ||
| -$571M-161% | -$219M-326% | $97M— | —— | ||
| $25.73B+103% | $12.68B+93.5% | $6.55B-3.7% | $6.81B+10.6% | ||
| $5.09B+144% | $2.09B+59.1% | $1.31B+134% | $561.6M-2.1% | ||
| $20.64B+94.9% | $10.59B+102% | $5.24B-16.1% | $6.24B+11.9% | ||
| 31.7%+8.2pp | 23.5%+8.2pp | 15.4%-6.5pp | 21.9%+2.2pp | ||
| $22.95+96.0% | $11.71+102% | $5.80-15.9% | $6.90+12.6% | ||
| $27.73B+91.9% | $14.45B+78.8% | $8.08B-3.0% | $8.33B+8.1% | ||
| 42.5%+10.5pp | 32.1%+8.4pp | 23.7%-5.5pp | 29.2%+2.0pp | ||
| $25.73B+103% | $12.68B+93.5% | $6.55B-3.7% | $6.81B+10.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Eli Lilly's revenue?
- Eli Lilly (LLY) generated $72.2B in revenue over the trailing twelve months, up 47.4% year over year.
- Is Eli Lilly profitable?
- Eli Lilly reported $25.3B in net income over the trailing twelve months, a 35.0% net margin.
- What is Eli Lilly's earnings per share?
- Eli Lilly's diluted EPS over the trailing twelve months is $28.15.
- Where does Eli Lilly's income statement data come from?
- Every line is extracted from Eli Lilly's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
